Advancing CAR T-Cell Therapy
This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.
Authors
- Upendra Mahat (ORCID: https://orcid.org/0000-0001-7272-0988)
- Asha Das (ORCID: https://orcid.org/0000-0003-4360-0092)
- Vinay Prasad
- Vijay Kumar (ORCID: https://orcid.org/0000-0001-6840-7913)
Institutions
- Center for Biologics Evaluation and Research (US)
- Center for Drug Evaluation and Research (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1001/jama.2025.21721
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09